Heska (NASDAQ:HSKA) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Monday.
A number of other brokerages have also issued reports on HSKA. Canaccord Genuity restated a “buy” rating and set a $115.00 target price (up from $100.00) on shares of Heska in a research report on Thursday, May 31st. TheStreet upgraded shares of Heska from a “c+” rating to a “b-” rating in a research report on Thursday, May 31st. B. Riley raised their target price on shares of Heska from $77.00 to $93.00 and gave the stock a “neutral” rating in a research report on Friday, May 18th. Zacks Investment Research lowered shares of Heska from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 23rd. Finally, Benchmark raised their target price on shares of Heska from $120.00 to $143.00 and gave the stock a “buy” rating in a research report on Monday, May 21st. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $115.25.
Shares of Heska opened at $105.48 on Monday, according to MarketBeat. The company has a market cap of $774.16 million, a PE ratio of 50.96 and a beta of 0.75. Heska has a 12-month low of $56.59 and a 12-month high of $115.00.
Heska (NASDAQ:HSKA) last announced its earnings results on Friday, May 4th. The medical research company reported $0.28 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.12). The business had revenue of $32.77 million for the quarter, compared to analysts’ expectations of $31.65 million. Heska had a return on equity of 13.30% and a net margin of 5.57%. research analysts predict that Heska will post 1.68 EPS for the current year.
In related news, Director Bonnie J. Trowbridge sold 5,000 shares of the stock in a transaction on Tuesday, May 29th. The stock was sold at an average price of $101.01, for a total transaction of $505,050.00. Following the completion of the sale, the director now directly owns 6,249 shares of the company’s stock, valued at $631,211.49. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Nancy Wisnewski sold 750 shares of the stock in a transaction on Friday, June 8th. The stock was sold at an average price of $106.50, for a total value of $79,875.00. Following the sale, the executive vice president now directly owns 34,873 shares of the company’s stock, valued at $3,713,974.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 26,202 shares of company stock valued at $2,752,523. Corporate insiders own 15.90% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp lifted its holdings in Heska by 110.1% in the fourth quarter. Bank of New York Mellon Corp now owns 210,669 shares of the medical research company’s stock valued at $16,897,000 after acquiring an additional 110,391 shares during the period. Rhumbline Advisers lifted its holdings in Heska by 13.3% in the fourth quarter. Rhumbline Advisers now owns 14,785 shares of the medical research company’s stock valued at $1,186,000 after acquiring an additional 1,731 shares during the period. Redmile Group LLC acquired a new stake in Heska in the fourth quarter valued at $15,753,000. Fred Alger Management Inc. lifted its holdings in Heska by 27.3% in the fourth quarter. Fred Alger Management Inc. now owns 139,120 shares of the medical research company’s stock valued at $11,159,000 after acquiring an additional 29,844 shares during the period. Finally, Park West Asset Management LLC lifted its holdings in Heska by 293.3% in the fourth quarter. Park West Asset Management LLC now owns 347,646 shares of the medical research company’s stock valued at $27,885,000 after acquiring an additional 259,256 shares during the period. 89.16% of the stock is owned by hedge funds and other institutional investors.
Heska Company Profile
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.